Seeking Alpha

Orexigen (OREX) reports a quarterly loss of $0.24 vs. an expected -$0.21, but is still hopeful...

Orexigen (OREX) reports a quarterly loss of $0.24 vs. an expected -$0.21, but is still hopeful about obesity drug Contrave : "we have been preparing for a meeting with FDA to discuss a viable path forward for Contrave... [and] have submitted to the Agency a specific, innovative, and robust proposal to assess cardiovascular risk..." (PR)

Check out Seeking Alpha’s new Earnings Center »

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs